Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.”In the company’s words, NCT07889505 on ClinicalTrials.gov
- Tested for
- Type 1 Diabetes Mellitus
- Main trialPhase 2
- “This study consists of 2 sub-studies, including Part A and Part B. Part A is intended to further characterize the pharmacokinetic (PK) profile of PS1 based on existing single ascending dose (SAD) and multiple ascending dose (MAD) data, while Part B is designed as an exploratory study to evaluate the potential clinical effects of PS1 in adults with newly diagnosed type 1 diabetes mellitus (T1DM). PS1 is a potential blood glucose-lowering medication being developed by Pharmasaga Co., Ltd. for the treatment of T1DM.”In the company’s words, NCT07889505 on ClinicalTrials.gov
Other drugs for Type 1 Diabetes Mellitus
- TirzepatideEli Lilly · Phase 3
- Insulin icodecNovo Nordisk · Phase 3
- CadisegliatinvTv Therapeutics · Phase 3
- Stem Cell Educator therapyYong Zhao, MD, PhD · Phase 3
- VX-017Vertex Pharmaceuticals · Phase 3
- VX-880Vertex Pharmaceuticals · Phase 3
Coming up1
- 15 Aug 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 15 Aug 2028 | A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes | |
| Phase 1Completed | 27 Apr 2026 | Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026